AC Immune Company Insiders

ACIU Stock  USD 2.73  0.02  0.74%   
AC Immune employs about 133 people. The company is managed by 17 executives with a total tenure of roughly 30 years, averaging almost 1.0 years of service per executive, having 7.82 employees per reported executive. Breaking down AC Immune's management performance can provide insight into the firm performance.
Andrea Pfeifer  CEO
CEO CoFounder
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AC Immune. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy ACIU Stock please use our How to Invest in AC Immune guide.

AC Immune's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with AC Immune's future performance. Based on our forecasts, it is anticipated that ACIU will maintain a workforce of slightly above 130 employees by January 2025.
 
Covid

AC Immune Management Team Effectiveness

The company has return on total asset (ROA) of (0.1204) % which means that it has lost $0.1204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3116) %, meaning that it created substantial loss on money invested by shareholders. AC Immune's management efficiency ratios could be used to measure how well AC Immune manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.33 in 2024. Liabilities And Stockholders Equity is likely to gain to about 193.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 12.8 M in 2024.
Common Stock Shares Outstanding is likely to drop to about 73.3 M in 2024. Net Loss is likely to gain to about (60.5 M) in 2024

AC Immune Workforce Comparison

AC Immune is rated third in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,579. AC Immune holds roughly 133 in number of employees claiming about 8% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.97) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.29 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.29.

AC Immune Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. AC Immune Price Series Summation is a cross summation of AC Immune price series and its benchmark/peer.

AC Immune Notable Stakeholders

An AC Immune stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AC Immune often face trade-offs trying to please all of them. AC Immune's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AC Immune's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Andrea PfeiferCEO CoFounderProfile
Julian SnowVP DevelopmentProfile
Nuno MDChief OfficerProfile
Christopher RobertsInterim FinProfile
Sonia PoliHead ScienceProfile
Piergiorgio DonatiChief OfficerProfile
Pr MDChief OfficerProfile
Joshua DrummHead RelationsProfile
JeanFabien MoninChief Administrative OfficerProfile
Howard DonovanChief OfficerProfile
Alexandre CaratschGeneral CounselProfile
Gary WaandersSenior CommunicationsProfile
Marie KoscoVilboisChief OfficerProfile
Judith MooreGlobal CommunicationsProfile
Madiha DerouaziChief OfficerProfile
Joseph WettsteinHead OfficerProfile
David HickmanHead SMEProfile

About AC Immune Management Performance

The success or failure of an entity such as AC Immune often depends on how effective the management is. AC Immune management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACIU management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACIU management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.41)(0.43)
Return On Capital Employed(0.32)(0.33)
Return On Assets(0.30)(0.31)
Return On Equity(0.34)(0.35)
Please note, the imprecision that can be found in AC Immune's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AC Immune. Check AC Immune's Beneish M Score to see the likelihood of AC Immune's management manipulating its earnings.

AC Immune Workforce Analysis

Traditionally, organizations such as AC Immune use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AC Immune within its industry.

AC Immune Manpower Efficiency

Return on AC Immune Manpower

Revenue Per Employee111.3K
Revenue Per Executive870.6K
Net Loss Per Employee407.8K
Net Loss Per Executive3.2M
Working Capital Per Employee838.9K
Working Capital Per Executive6.6M

Additional Tools for ACIU Stock Analysis

When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.